Global Iron Deficiency Anemia Therapy Market Size study, by Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy), Age Group, End-user, and Regional Forecasts 2022–2032

The Global Iron Deficiency Anemia Therapy Market is valued at approximately USD 4.83 billion in 2023 and is poised to expand at a healthy CAGR of more than 7.60% over the forecast period 2024–2032. Iron deficiency anemia (IDA), a condition that affects oxygen transport in the body due to insufficient iron levels, continues to be a widespread and undertreated health challenge. The growing prevalence of nutritional deficiencies, pregnancy-related anemia, chronic blood loss, and gastrointestinal disorders is significantly influencing market growth. The increasing demand for therapeutic interventions that range from oral supplementation to intravenous iron therapies is reshaping how healthcare systems and patients approach IDA management, especially in emerging markets and underserved populations.

Over the years, oral iron therapy has remained the first-line treatment for mild to moderate cases of IDA owing to its cost-effectiveness and ease of administration. However, patient non-compliance due to gastrointestinal side effects has driven a surge in preference for parenteral iron therapies, which offer faster iron repletion and improved bioavailability. Innovations such as iron polymaltose complexes and ferric carboxymaltose are being strategically deployed to address chronic conditions like chronic kidney disease (CKD) and inflammatory bowel disease (IBD), where oral iron absorption is often compromised. Alongside these developments, pediatric and geriatric populations are receiving increasing attention with tailored formulations that cater to specific metabolic and physiological requirements.

A growing body of clinical guidelines advocating for early intervention and iron profiling is prompting a paradigm shift from symptomatic treatment to proactive screening and individualized therapy. As awareness campaigns and nutrition-based public health programs expand, iron therapy is gaining acceptance in broader demographics, including menstruating women, adolescents, and postpartum mothers. Healthcare providers are now emphasizing patient-centric approaches that optimize dosing frequency and minimize side effects, while pharmaceutical manufacturers are accelerating R&D investments into next-generation delivery mechanisms. Digital health integration is further enhancing adherence monitoring and outcome tracking, particularly in high-risk patient cohorts.

Regionally, North America commands a significant share of the global market due to its well-structured healthcare infrastructure, reimbursement frameworks, and rising prevalence of chronic ailments such as CKD and cancer-associated anemia. Europe follows closely, buoyed by national anemia reduction initiatives and high awareness levels among women and children. Meanwhile, the Asia Pacific region is witnessing the fastest growth trajectory, driven by a large anemic population base, rapid urbanization, and increased government funding for maternal and child health. Countries like India and China are particularly pivotal, with their extensive rural outreach programs and efforts to reduce micronutrient malnutrition.

Major market player included in this report are:
• Sanofi S.A.
• Vifor Pharma Ltd.
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• AMAG Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Mylan N.V.
• Zydus Lifesciences Ltd.
• Bayer AG
• Cipla Ltd.
• Akebia Therapeutics, Inc.
• Rockwell Medical, Inc.

The detailed segments and sub-segment of the market are explained below:

By Therapy Type
• Oral Iron Therapy
• Parenteral Iron Therapy

By Age Group
• Pediatric
• Adult
• Geriatric

By End-user
• Hospitals
• Clinics
• Homecare
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.